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Influenza pandemics and seasonal outbreaks have shown the potential of Influenza A
virus (IAV) to enhance susceptibility to a secondary infection with the bacterial pathogen
Streptococcus pneumoniae (Sp). The high morbidity and mortality rate revealed the
poor efficacy of antiviral drugs and vaccines to fight IAV infections. Currently, the most
effective treatment for IAV is by antiviral neuraminidase inhibitors. Among them, the
most frequently stockpiled is Oseltamivir which reduces viral release and transmission.
However, effectiveness of Oseltamivir is compromised by the emergence of resistant
IAV strains and secondary bacterial infections. To date, little attention has been given to
evaluate how Oseltamivir treatment strategies alter Influenza viral infection in presence
of Sp coinfection and a resistant IAV strain emergence. In this paper we investigate
the efficacy of current approved Oseltamivir treatment regimens using a computational
approach. Our numerical results suggest that the curative regimen (75 mg) may yield
47% of antiviral efficacy and 9% of antibacterial efficacy. An increment in dose to 150
mg (pandemic regimen) may increase the antiviral efficacy to 49% and the antibacterial
efficacy to 16%. The choice to decrease the intake frequency to once per day is not
recommended due to a significant reduction in both antiviral and antibacterial efficacy. We
also observe that the treatment duration of 10 days may not provide a clear improvement
on the antiviral and antibacterial efficacy compared to 5 days. All together, our in silico
study reveals the success and pitfalls of Oseltamivir treatment strategies within IAV-Sp
coinfection and calls for testing the validity in clinical trials.
Keywords: viral infection, S. pneumoniae coinfection, Oseltamivir treatment, PK/PD model, microbial resistance,
population modeling, viral dynamic model
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1. INTRODUCTION
Influenza A virus (IAV) and Streptococcus pneumoniae (Sp)
are common causative agents of morbidity and mortality,
respectively (Kilbourne, 2006; Morens et al., 2008; World Health
Organization, 2009a). Over the last century four major influenza
pandemics in 1918, 1957, 1968, and 2009 have had a significant
impact worldwide. The Great Pandemic also known as the
Spanish flu of 1918/1919 is considered as the deadliest pandemic
with an estimated mortality of about 100 million around the
globe (Johnson and Mueller, 2002). Interestingly, during the
1918 pandemic over 71% of the blood and sputum samples
from fatal victims tested positive for Sp (Louria et al., 1959;
McCullers and Rehg, 2002; McCullers, 2006, 2014), indicating a
clear predisposition to lethal secondary bacterial infection in IAV
preinfected patients.
Even though the mortality rate due to coinfections has
decreased during the succeeding pandemics mostly because
of antibiotic implementation, it still remains to be the most
likely cause of death in 10–55% of the 2009 H1N1 victims.
Thus, bacterial coinfection is a critical clinical outcome of viral
infection and great attempts have been made to understand the
pathogenesis and treatment course. The underlying mechanism
for copathogenesis has been widely studied in animal models,
providing evidence for a multifaceted disease affecting both lung
physiology and immune responses (Shahangian et al., 2009; Small
et al., 2010; Kash et al., 2011; Li et al., 2012). IAV-mediated
immune aberrations such as immune cell dysfunction and
apoptosis, dysregulated cytokine milieu and immunopathology
in the lungs (Murray et al., 2014) have been implicated to have
both immediate and long-term effects on anti-pneumococcal
defense. The impact of coinfection is not limited to the bacterial
outgrowth but also impairs antiviral immunity. Therefore, it
is important for clinical treatment of coinfections to have
a combinatorial approach to focus on all aspects of disease
pathogenesis: the virus, bacteria, and host immune responses.
For prevention and treatment of acute IAV infection,
antiviral drugs are an important adjunct to influenza vaccines
(Goldstein and Lipsitch, 2009). The most commonly used
Food and Drug Administration approved (FDA) antiviral drugs
are neuraminidase inhibitors, e.g., Zanamivir, Peramivir, and
Oseltamivir. The viral neuraminidase is an enzyme found on
IAV surface enabling IAV virions to be released from the
infected host cell. The neuraminidase inhibitors block this
activity, thus interfering with viral spread and infectivity in the
lungs (Moscona, 2005). In vivo administration of Oseltamivir is
effective in controlling viral loads and immunopathology during
lethal infection (McNicholl and McNicholl, 2001). In humans,
the drug reduces clinical symptoms by 0.7–1.5 days when
treatment is started 2 days after laboratory confirmed influenza,
representing great potential if used appropriately to prevent the
development of resistance (McNicholl and McNicholl, 2001).
In the case of coinfections, the murine study in McCullers
(2004) showed that treatment with Oseltamivir improved the
survival by 75% in the coinfected group which further improved
after combinatorial therapy with ampicillin. The first line of
therapy following pneumococcal pneumonia is penicillin or
other beta lactams, however the higher inflammatory status
of the lung following coinfection with highly pathogenic virus
strains may call for the use of non-lytic bacteriostatic agents
such as clindamycin and azithromycin (Karlström et al., 2009).
Furthermore, the anti-inflammatory and immunomodulatory
action of corticosteroids used to treat many immune diseases
could have a potent additive effect. In fact, the in vivo murine
study by Trappetti et al. (2009) suggested a positive role of
neuraminidase in Sp biofilm formation, thus Oseltamivir would
be beneficial in preventing colonization. Following this study,
the inhibiting effect of the approved anti-IAV drugs (Oseltamivir
and Zanamivir) on Sp neuraminidase was confirmed by an
in vitro kinetic study (Gut et al., 2011). Despite the existing
combinatorial therapies against coinfections, the cumulative
effect of neuraminidase inhibitor (Oseltamivir), the correct
antibiotic and corticosteroids (Dexamethasone) is yet to be
studied. With the increase in Oseltamivir use, drug resistant
IAV strains may emerge bearing mutations such as H275Y
in neuraminidase (Sheu et al., 2008). So far, the potentially
detrimental effect of such mutant virus strains on secondary
bacterial infections remains elusive.
The effectiveness of the Oseltamivir treatment depends on the
dose regimen, intake frequency, time delay between infection
and treatment, and treatment duration. The antiviral efficacy
of neuraminidase inhibitors such as Oseltamivir, Amantadine
and Peramivir has been investigated experimentally (Tanaka
et al., 2015) and theoretically (Handel et al., 2007; Canini
et al., 2014; Kamal et al., 2015). Recently, pharmaceutical
companies have taken a strategic initiative to promote the use
of modeling approaches within drug projects. The value of
a model-based approach for improved efficiency and decision
making during the preclinical stage of drug development has
been largely advocated (Visser et al., 2013). Drug administration
considers mainly two phenomena, i.e., the pharmacokinetic (PK)
and pharmacodynamic (PD). The PK regards the temporal
distribution of drug concentration in different organs of host
body, while the PD describes the effect of a drug on the organism
(Lahoz-Beneytez et al., 2015).
To the best of our knowledge, Oseltamivir treatment
strategies for IAV infection in presence of Sp coinfection
and a resistant IAV strain has not been investigated. In this
paper, we tested the approved Oseltamivir treatment efficacy,
combining a mathematical model of IAV-Sp coinfection with
the PK/PD model of Oseltamivir. A possible emergence of
an IAV Oseltamivir-resistant strain is also considered. Our
computational results showed that Oseltamivir treatment with
a dose of 150mg, twice per day for 5 days is the minimum
requirement recommended to achieve an antiviral efficacy of
49% and an antibacterial efficacy of 16%. Moreover, we found
that in case of 75mg dose administration, the intake frequency
should not be lower than twice per day. A prolongation of
the treatment up to 10 days with an intake frequency of twice
per day, did not produce a clear benefit in terms of efficacy.
This theoretical framework revealed the success and pitfalls of
Oseltamivir strategies within IAV-Sp coinfection, paving the way
for further refinement of therapeutic applications and clinical
trials.
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2. MATERIALS AND METHODS
2.1. PK/PD Model of Oseltamivir
The PK model of Oseltamivir consists of a two compartment
model (Rayner et al., 2008; Wattanagoon et al., 2009; Canini
et al., 2014), one for Oseltamivir phosphate (OP) and one for
its active metabolic compound form Oseltamivir Carboxylate
(OC). The system of ordinary differential equations describing
the concentrations of OP and OC is as follows:
G˙ = −kaG, (1)
O˙P = kaG− kfOP, (2)
O˙C = kfOP − keOC, (3)
where G is the depot compartment representing the OP dose
administered, before it is adsorbed inside the blood with the
adsorption rate ka. The parameter kf is the conversion rate from
OP toOC and ke is theOC elimination rate. The initial conditions
of this system are G(0) = Dose, OP(0) = 0, OC(0) = 0. As
the explicit effect of OC is to inhibit the viral release of IAV
from infected cells, we modeled in similar vein to Canini et al.
(2014) the OC action by modifying the viral replication rate to
p = (1 − ǫS(t))p, where ǫS(t) is the time varying drug efficacy
defined as a function of OC concentration:
ǫS(t) =
OC
ECS50 + OC
. (4)
ECS50 is the OC concentration providing the 50% of drug efficacy.
Cell culture assays found the values of ECS50 in the range [0.0008−
35] µM (Tamiflu (R), 2009). Simulation environments will be
based on values of ECS50 equal to 0.5, 10, and 35 µM.
2.2. IAV-Pneumococcus Coinfection Model
The scheme of the mathematical model of IAV-Sp coinfection
and Oseltamivir interaction is illustrated in Figure 1. The
dynamic of the IAV Oseltamivir-sensitive strain V is described
by the target cell model with the eclipse phase (Nowak and
May, 2000; Baccam et al., 2006; Beauchemin and Handel, 2011;
Boianelli et al., 2015). Then, this is incorporated with the
mathematical model of IAV-Sp coinfection proposed by Smith
et al. (2013). We denote with U the uninfected cells, I1 the non
FIGURE 1 | Mathematical model for IAV-Sp coinfection with the antiviral Oseltamivir carboxylate OC. The IAV sensitive strain V and resistant mutant strain
VR (H275Y) are cleared at rate c. The uninfected cells become non productively infected cells I1 and J1 at the rate β by V and VR respectively. I1 and J1 become
productively infected cells at the rate k, that is I2 and J2 respectively. V and VR replicate at the rate p(1− µ) and µp respectively. I2 and J2 are cleared at rate δ. The
bacteria B proliferate at the rate m and increase the viral replication rate a. In turn V and VR increase the bacterial carrying capacity with the parameter φ.
Macrophages MA phagocytose the bacteria with the rate γM f (B,MA ). The phagocytosis rate is decreased by V and VR with the parameter ψ . Bacteria increase the
toxicity rate of non productively and productively infected cells of V and VR with the rate parameter η. The Oseltamivir carboxylate OC decreases the V and VR viral
replication rate p to p(1− ǫS (t)) and p(1− ǫR (t)) respectively.
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productively infected cells, I2 the productively infected cells. U
is infected by V with infection rate β . 1/k is the average time
in which I1 cells become productively infected cells. δ is the
clearance rate of productively infected cells I2 while p is the
viral replication rate of V by I2. c is the viral clearance rate of
V . We fix the initial number of uninfected cells U(0) at 107.
The initial conditions for the sensitive strain V and Sp B are
in Table 2, while for the others model variables are set to zero.
The IAV and Sp initial conditions for performing simulations
are in the concentration units of TCID50mL−1 and CFUmL−1.
The volume (mL) in the initial condition refers to the volume
used (50 µL) in Smith et al. (2013) for the IAV and Sp (D39
strain) inoculum. According to the effect of OC on productively
infected cells, the viral replication rate p is modified in p(1 −
ǫS(t)). We assume that an IAV Oseltamivir-resistant mutant
strain (H275Y) VR could emerge from the sensitive type as a
consequence of Oseltamivir treatment (Sheu et al., 2008; World
Health Organization, 2010; Chen et al., 2011; Dobrovolny et al.,
2011; Renaud et al., 2011). The kinetic parameters of VR are
assumed equal to those of V . The emergence of VR is considered
to be with the probability µ. VR and V can compete for the
same target cells U (Govorkova et al., 2010). Then, we denote
with J1 and J2 the non productively and productively infected
cells respectively of VR, where ǫR(t) is the Oseltamivir efficacy
against VR having the same form in (4). It has been shown that
for VR, ECR50 is 400 times higher than those for V (Gubareva
et al., 2001). We also explore the case where it is 200 times
higher.
To investigate the synergy between IAV and Sp, Smith et al.
(2013) modeled the bacteria dynamics and interaction with
alveolar macrophages MA. The macrophages phagocytosis rate
γMf (B,MA) of free bacteria is expressed by the mathematical
function γMn2MA/(n2MA + B2), where n is the maximum
number of bacteria phagocytosed per MA, γM is the maximum
phagocytosis rate.MA cells number is considered in quasi steady
state, denoted as M∗A. Thus, the phagocytosis rate f (B,MA) is a
decreasing function of B. The pneumococcus growth is assumed
to be logistic with rate m and carrying capacity KB. The IAV is
assumed to increase the pneumococcal adherence to epithelial
cells. This is translated by increasing the bacterial carrying
capacity KB(1 + φV) where φ is a proportionality constant.
Moreover, another contribution of the IAV is the decreased
rate of phagocytosis by MA. This effect is included with the
saturation function ψV/(KPV + V), where ψ is the maximal
reduction of the phagocytosis rate and KPV is the half saturation
constant. On the other hand, the pneumococcus effects on
the IAV that may cause viral rebound are unknown. One
plausible hypothesis assumes that the bacterial neuraminidase
supports the viral neuraminidase to enhance the viral particle
release from infected cells (McCullers, 2014). This is taken
into account by considering an additional term in the viral
replication rate p(1 + aBz), where z is the nonlinearity order
coefficient and a is the positive term of bacterial effect. The
model also included the toxicity effect of B on I1, J1, and I2,
J2 with the toxicity rate η. This model is extended including
the dynamics of the resistant virus, assuming that VR influences
B in the same way of V and vice versa. The modified
model is as follows:
U˙ = −βU(V + VR), (5)
I˙1 = βUV − kI1 − ηBI1, (6)
I˙2 = kI1 − δI2 − ηBI2 (7)
J˙1 = βUVR − kJ1 − ηBJ1, (8)
J˙2 = kJ1 − δJ2 − ηBJ2, (9)
V˙ = (1− µ)p(1+ aBz)(1− ǫS(t))I2 − cV, (10)
V˙R = µp(1+ aB
z)((1− ǫS(t))I2 + (1− ǫR(t))J2)− cVR,(11)
B˙ = mB
(
1−
B
KB(1+ φ(V + VR))
)
−γM
n2M∗A
n2M∗A + B
2 B
(
1−
ψ(V + VR)
V + VR + KPV
)
. (12)
The parameters value used for our population approach are
in Table 1. These values represent the median value estimated
in Canini et al. (2014), Wattanagoon et al. (2009) and Smith
et al. (2013). More specifically, IAV-Sp model parameters were
estimated from adult mice in Smith et al. (2013). It should be
noted that kinetics and time scales of viral titer as well as immune
parameters estimated from murine data can offer a reasonable
approximation of IAV-Sp dynamics in humans (Small et al., 2010;
Beauchemin and Handel, 2011). The parameter µ was estimated
from human studies in Hayden (2001), as well as the Oseltamivir
PK/PDmodel was inferred for human adults (Wattanagoon et al.,
2009).
2.2.1. Drug Regimen Evaluation
The approved regimens stated by the guidelines for Oseltamivir
administration in human adults (World Health Organization,
2009b; Canini et al., 2014) are: 75 mg twice per day for
5 days (curative regimen), 150 mg twice per day for 5
days (recommended regimen for pandemic influenza). These
regimens are shown in Table 2 as a benchmark for the
treatment evaluation. Oseltamivir regimens were evaluated with
the antiviral efficacy index defined in Canini et al. (2014) as:
VEFF = 1−
AUCVT + AUCRT
AUCV + AUCR
, (13)
where AUCVT and AUCRT are the area under the curve of V
and VR in presence of treatment, while AUCV and AUCR are the
area under the curve without treatment. We also computed the
antibacterial efficacy of the Oseltamivir treatment:
BEFF = 1−
AUCBT
AUCB
, (14)
where AUCBT and AUCB are the area under the curve of the
bacterial time course with and without treatment.
2.2.2. Population Approach
In order to take into account the individual heterogeinity
observed in vivo (Canini and Carrat, 2011), we performed 10,000
simulations by sampling from a uniform distribution centered
in the estimated values of Table 1 with a variation of ±30%.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4 June 2016 | Volume 6 | Article 60
Boianelli et al. In silico Oseltamivir Treatments against Influenza-Pneumococcus Coinfection
TABLE 1 | IAV-Sp and PK/PD Oseltamivir model parameters with ranges used for the population approach.
Parameter Definition Median (Range)a Unit References
IAV-Sp MODEL PARAMETERS
β Virus infectivity 2.8 (1.96 3.64) ×10−6 TCID50mL
−1 Smith et al., 2013
k Eclipse phase 4.0 (2.8 5.2) day−1 Smith et al., 2013
δ Productive cell clearance rate 0.89 (0.62 1.16) day−1 Smith et al., 2013
p Viral replication rate 25.1 (17.7 32.89) TCID50mL
−1day−1 Smith et al., 2013
c Viral clearance rate 28.4 (19.88 36.92) day−1 Smith et al., 2013
η Toxicity of infected cell rate 5.2 (3.64 6.76) ×10−10 CFU mL−1 Smith et al., 2013
µ Resistant virus appearance rate 2 (1.4 2.6) ×10−6 adim Hayden, 2001
φ Increase in carrying capacity 1.2 (0.84 1.56) ×10−8 TCID50mL
−1 Smith et al., 2013
ψ Decrease in phagocytosis rate 0.87 (0.61 1.13) adim Smith et al., 2013
a Positive feedback rate 1.2 (0.84 1.56) ×10−3 CFU mL−z Smith et al., 2013
m Bacterial growth rate 27 (19 35) day−1 Smith et al., 2013
KB Pneumococcus carrying capacity 2.3 (1.61 2.99) ×10
8 CFUmL−1 Smith et al., 2013
KPV Half saturation constant 1.8 (1.26 2.34) ×10
3 TCID50mL
−1 Smith et al., 2013
γM Macrophages phagocytosis rate 1.35 (0.95 1.75) ×10
−4 cell−1day−1 Smith et al., 2013
n Maximum bacteria number for MA 5.0 (3.5 6.5) CFUmL
−1 cell−1 Smith et al., 2013
z Non linear coefficient 0.5 (0.35 0.65) adim Smith et al., 2013
OSELTAMIVIR PK/PD PARAMETERS
ka OP adsorption rate 1.01 (0.7 1.31) h−1 Wattanagoon et al., 2009
kf OP conversion rate in OC 0.684 (0.48 0.88) h
−1 Wattanagoon et al., 2009
ke OC clearance rate 0.136 (0.09 0.177) h−1 Wattanagoon et al., 2009
aParameter ranges used for the population approach. The values are computed with ± 30% of variation from the median values.
The volume (mL) in model parameters was related to the total volume used (50 µL) in Smith et al. (2013) for the IAV and Sp (D39 strain) inoculum.
Model parameter ranges are showed in Table 1. We computed
the antiviral and antibacterial efficacy defined in Equations (13)–
(14) of the curative regimen with 75, 150, 300, and 450mg, twice
per day for 5 days. Moreover, a different intake frequency of
once per day for 5 days with dosage of 75 mg was explored. A
different treatment duration of 10 days with 75mg and intake
frequency of twice per day was also investigated. In order to
mimic a realistic scenario, we assumed a random sampling for
the starting time of drug treatment, time of coinfection and initial
values of viral and bacterial titers. In fact, the amount of viral and
bacterial burden is unknown when an individual is infected by
IAV and Sp. Moreover, it is also unknown after how many days
post the infection time the antiviral treatment is started. This is
because the time of infection is not known. In the same way, the
time of coinfection is typically unknown in naturally acquired Sp
coinfection. The ranges of experimental values are presented in
Table 2. For the correct viral dynamics simulation, we imposed
the viral titer V to be constant when it crosses lower values than
the threshold of 2.8×10−7 TCID50mL−1. The minimum therapy
initiation time was considered starting at 2 days post infection,
because at this time symptoms are clearly visible (Aoki et al.,
2003; Louie et al., 2012; Muthuri et al., 2012).
2.2.3. Statistical Analysis
We performed the one way ANOVA statistical significance
test and then Bonferroni test on the 10,000 stochastic
simulations. The statistical significance difference for antiviral
and antibacterial distributions between the 75mg dose (curative
regimen) and 150 (pandemic regimen), 300, and 450mg were
TABLE 2 | Simulation settings and approved Oseltamivir treatment
regimens.
Variable Range Units
Therapy initiation time [2 3 4] days
Time of pneumococcus
coinfection after influenza infection
[4 5 6 7] days
Intial viral load/titer [2 100] TCID50mL
−1
Initial pneumococcal (D39 strain)
load
[20 600] CFU mL−1
APPROVED REGIMENS (World Health Organization, 2009b)
Dose Intake frequency Treatment duration
75 mg (curative) Twice per day 5 days
150 mg (pandemic) Twice per day 5 days
The volume (mL) was related to that used (50 µL) in Smith et al. (2013) for the IAV and Sp
(D39 strain) inoculum.
computed. We compared also the curative regimen intake
frequency of twice per day with intake frequency of once per day.
Moreover, we investigated the statistical significance between
treatment duration of 5 and 10 days. The comparison is done for
ECS50 values of 0.5, 10, and 35 µM.
2.2.4. Sensitivity Analysis
To analyse to which extent each parameter affected the model
outputs, we simulated the viral and bacterial dynamics by
changing the parameters in Table 1 once per time of 10, 30 and
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50% and keeping the others fixed (see Supplementary Figures
S4, S5).
3. RESULTS
3.1. Influence of Oseltamivir Dose
In this section we evaluated the antiviral and antibacterial
efficacy for Oseltamivir dose of 75, 150, 300, 450mg, twice
per day for a treatment duration of 5 days. Figure 2 displays
histograms obtained for different doses and ECS50. The histograms
represent the distribution of antiviral and antibacterial efficacy
values computed from 10,000 samples. Tables 3 and 4 show the
median values of antiviral and antibacterial efficacy for different
doses and ECS50 values. Interestingly, the antibacterial efficacy
histograms in Figure 2 presented a bimodal distribution for both
different doses and ECS50 values. The antibacterial dichotomymay
be a result of two factors. The first could be attributed to the
bacterial growth rate (m) and macropaghes phagocytosis rate
(γM), greatly affecting Sp dynamics. The second refers to IAV
parameters responsible for macrophages phagocytosis decrease
(Kpv) and bacterial carrying capacity increase (φ) that influence
the pneumococcal time course as well (Supplementary Figure
S5). Then, combinations of these viral and bacterial parameters
can promote alternatively bacterial colonization or bacterial
clearance. This implies that in favorable conditions, Oseltamivir
treatment strategies may be able to inhibit viral dynamics
(high antiviral efficacy) and in turn modulate bacterial growth
(high antibacterial efficacy). Otherwise, in worst scenarios,
Oseltamivir treatment strategies may fail to control bacterial
dynamics.
For the best scenario where Oseltamivir treatment is effective
(ECS50 = 0.5 µM), the first set of 10,000 simulations revealed
that the distribution of antiviral and antibacterial efficacy were
significantly different by changing the dose from 75 to 150mg.
In fact, for the curative regimen of 75mg, the antiviral efficacy
median value was 47%, remaining quite stable for higher values
of dose (49%). The same pattern was conserved for higher values
of ECS50, where for the highest dosage tested (450mg), the median
antiviral efficacy values were 45 and 28.9%, while for the curative
regimen were 22 and 8.7% respectively. Concurrently, in Table 4,
the antibacterial efficacy for the curative regimenwith ECS50 = 0.5
µM presented a value of 9% that further decreased to 0.3% for
FIGURE 2 | Histograms of the antiviral (green) and antibacterial efficacy (grey) for different Oseltamivir dose of 75, 150, 300, and 450mg, with intake
frequency of twice per day and a duration of 5 days for (A) ECS
50
= 0.5 µM, (B) ECS
50
= 10 µM, and (C) ECS
50
= 35 µM. The x-axis represents the Oseltamivir
antiviral/antibacterial efficacy against IAV ranging from 0 (0%) to 1 (100%).
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TABLE 3 | Antiviral efficacy median values for different ECS
50
and different
dose regimens with intake frequency of twice per day and treatment
duration of 5 days.
Dose (mg) ECS
50
(µM)
0.5 10 35
75 0.47* 0.22* 0.087*
150 0.49* 0.31* 0.153*
300 0.49 0.40* 0.237*
450 0.49 0.45* 0.289*
*Statistically significant.
For ECS50 = 0.5 µM, statistically significant difference was observed between the antiviral
efficacy distributions for the dose of 75 and 150 mg (P < 0.05), while significant
differences were found (P < 0.05) between all the dose for ECS50 = 10, 35 µM.
TABLE 4 | Antibacterial efficacy median values for different ECS
50
and
different dose regimens with intake frequency of twice per day for a
duration of 5 days.
Dose (mg) ECS50 (µM)
0.5 10 35
75 0.09* 0.010* 0.003*
150 0.16* 0.017* 0.006*
300 0.31* 0.030* 0.010*
450 0.41* 0.036* 0.015*
*Statistically significant.
For ECS50 = 0.5, 10, 35 µM, the differences between the antibacterial efficacy for all doses
of 75, 150, 300, and 450mg were statistically significant (P < 0.05).
ECS50 = 35 µM. Similarly, for 450mg, the antibacterial efficacy
dropped from 41 to 1.5%.
We also investigated the sensitivity of the Oseltamivir antiviral
and antibacterial efficacy with respect to the ECR50 values. The
previous results were with ECR50 = 400 × EC
S
50. Thus, we
tested the same treatment regimens of 75, 150, 300, and 450mg
with intake frequency of twice per day, for 5 days where
ECR50 = 200×EC
S
50. We computed the antiviral and antibacterial
efficacy for the previous existing three different values of ECS50
(see Supplementary Figure S1). Histograms of antiviral and
antibacterial efficacy presented the same properties observed
when ECR50 = 400 × EC
S
50. More specifically, in agreement
with the previous case with ECR50 = 400 × EC
S
50, a statistically
significant difference was observed between 75 and 150 mg for
the lowest value of ECS50. We noted similar median values of the
antiviral efficacy for different doses and ECS50 with respect to the
case where ECR50 = 400×EC
S
50. In the same way, the antibacterial
efficacy for 200 and 400 times the value of ECS50 also presented
consistent values (see Supplementary Tables S1, S2).
3.2. Role of Oseltamivir Intake Frequency
In order to investigate the effect of the intake frequency treatment
on the coinfection course dynamics, we simulated in another set
of 10,000 simulations, the administration of 75 mg dose with
intake frequency of once per day, for 5 days. These treatment
regimens are explored for the same values of ECS50 considered
TABLE 5 | Comparison of antiviral and antibacterial efficacy median
values for different ECS
50
values with intake frequency of once and twice
per day and treatment duration of 5 days.
Intake frequency ECS50 (µM)
0.5 10 35
ANTIVIRAL EFFICACY
Twice per day 0.47* 0.22* 0.09*
Once per day 0.43* 0.135* 0.04*
ANTIBACTERIAL EFFICACY
Twice per day 0.09* 0.010* 0.005*
One per day 0.04* 0.005* 0.002*
*Statistically significant.
Statistical significance difference of antiviral/antibacterial efficacy distributions (P < 0.05)
was obtained between different intake frequency of once and twice per day.
previously and with the value of ECR50 = 400 × EC
S
50. The
antiviral and antibacterial efficacy values are reported in Table 5.
Histograms obtained from 10,000 simulations are shown in
Figure 3.
Both antiviral and antibacterial histogram values significantly
decreased when the intake frequency was once per day or for
higher ECS50. The bimodal distribution was conserved for the
antibacterial histograms due to reasons stated previously. The
distributions of antiviral and antibacterial efficacy presented
statistically significant difference (P < 0.05) for both different
values of intake frequency and ECS50. Notably, the values in
Table 5 with intake frequency of once per day were lower
compared to the median values of the antiviral efficacy of the
curative regimens for different values of ECS50. Therefore, the
antibacterial efficacy medians with intake frequency of once per
day showed approximately half values with respect to those with
intake frequency of twice per day. These results stressed the
importance of intake frequency to determine the clearance of
the IAV-Sp coinfection. Furthermore, the case where ECR50 =
200 × ECS50 (Supplementary Figure S2) was also investigated,
noting that in this regimen both the antiviral and antibacterial
efficacy medians possessed similar ranges compared with those
obtained when ECR50 = 400 × EC
S
50 (see Supplementary
Table S3).
3.3. Effect of Treatment Duration
In order to test the influence of the treatment duration on the
Oseltamivir efficacy against coinfection dynamics, we assumed
the possibility of treatment duration of 10 days with dose of 75
mg and intake frequency of twice per day. The median values of
antiviral and antibacterial efficacy are in Table 6. The histograms
showing the antiviral and antibacterial efficacy distributions
obtained from 10,000 simulations for different ECS50 values are
presented in Figure 4.
Antiviral efficacy distributions for treatment duration of 5 and
10 days show similar median values for all of ECS50 (no statistical
significance differences are noted, P > 0.05). Moreover, the
antibacterial efficacy with treatment durations of 5 and 10 days
confirmed the same pattern, in particular for ECS50 = 10 µM. We
also investigated the same treatment regimens using the value of
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FIGURE 3 | Histograms of the antiviral (green) and antibacterial (grey)
efficacy for the dose of 75 mg and intake frequency of once per day,
with the duration of 5 days for (A) ECS
50
= 0.5 µM, (B) ECS
50
= 10 µM, (C)
ECS
50
= 35 µM. The x-axis represents the Oseltamivir antiviral/antibacterial
efficacy against IAV/Sp ranging from 0 (0%) to 1 (100%).
TABLE 6 | Comparison of antiviral and antibacterial efficacy medians for
different ECS
50
values and intake frequency of twice per day with the
treatment duration of 5 and 10 days.
Treatment duration ECS
50
(µM)
0.5 10 35
ANTIVIRAL EFFICACY
5 days 0.47 0.22 0.09
10 days 0.52 0.24 0.10
ANTIBACTERIAL EFFICACY
5 days 0.08 0.01 0.005
10 days 0.12 0.01 0.003
For the antiviral/antibacterial efficacy, statistical significance difference was not found
(P > 0.05) for both treatment durations and different ECS50 values.
ECR50 = 200×EC
S
50 (see Supplementary Figure S3). In this setting
also the antiviral efficacy distributions with treatment durations
for 5 and 10 days were not statistically significant. We noted
similar median values for the antiviral and antibacterial efficacy
when ECR50 = 200 × EC
S
50 (see Supplementary Table S4), for
all the values of ECS50 considered. Overall analysis suggested that
the resistant mutant strain behavior may not really altered the
efficacy of the Oseltamivir against IAV-Sp coinfection.
FIGURE 4 | Histograms of the antiviral (green) and antibacterial (grey)
efficacy for the dose of 75mg and intake frequency of twice per day
with the duration of 10 days for (A) ECS
50
= 0.5, (B) ECS
50
= 10 µM, (C)
ECS
50
= 35 µM. The x-axis represents the Oseltamivir antiviral/antibacterial
efficacy against IAV/Sp ranging from 0 (0%) to 1 (100%).
4. DISCUSSION
In the last decades many mathematical models have been
developed describing the IAV infection dynamics in different
hosts (Baccam et al., 2006; Tridane and Kuang, 2010; Hernandez-
Vargas and Meyer-Hermann, 2012; Smith et al., 2013; Canini
and Perelson, 2014; Boianelli et al., 2015), and in presence of
treatment (Beauchemin and Handel, 2011; Canini and Perelson,
2014; Canini et al., 2014; Boianelli et al., 2015). However, the
history of IAV pandemics have highlighted the role of the
secondary bacterial infection in the increased morbidity and
mortality. To date, the only mathematical model describing the
IAV-pneumococcus coinfection was developed by Smith et al.
(2013).
In this paper, we extend the coinfection model from
Smith et al. (2013), by adding the pharmacokinetic and
pharmacodynamic effects of Oseltamivir and taking into account
a possible emergence of resistant mutant strain (H275Y)
induced by Oseltamivir treatment. In our model, we simulate
the intra-subject variability of influenza infection and also
a time dependent Oseltamivir drug efficacy. We test the
capability of the current approved Oseltamivir treatment
regimens to achieve antiviral and antibacterial efficacy in a
stochastic environment. Here, we simulate a more realistic
scenario for coinfection and Oseltamivir treatment strategies.
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For example, we assume a random time of treatment as we
do not know the delay between viral infection and treatment
initiation. Secondly, we consider the time of coinfection
randomly, because the time of secondary Sp infection is
unknown. Moreover, in real life infection the exact amount
of the viral and bacterial burden is usually unknown as well.
The possibility of different intake frequencies and treatment
duration according to the approved treatment regimens is
explored.
Our results show that the curative regimen (75mg for 5 days,
twice per day) may offer the 47% of antiviral efficacy and 9% of
antibacterial efficacy only in the case where the Oseltamivir is
effective (ECS50 = 0.5 µM) against IAV. Increasing the dose from
75 to 150mg with the same value of ECS50 results in a statistically
significant gain in terms of antiviral (49%) and antibacterial
efficacy (16%). Then, for the case of IAV-Sp coinfection, the
pandemic regimen could be recommended. Moreover, increasing
the dose may not represent a reasonable gain of antiviral and
antibacterial efficacy. However, in the case of the lowest efficiency
of Oseltamivir (ECS50 = 35µM), a significant increase in antiviral
and antibacterial efficacy is obtained with a dose of 450mg. With
this dose, twice per day, for 5 days, antiviral and antibacterial
efficacy display 28.9 and 1.5% median values, respectively. In
the same range of treatment strategies for the value of ECR50 =
200 × ECS50 the antiviral and antibacterial efficacy presented
no significant differences compared to the case where ECR50 =
400 × EC50. Moreover, reducing the intake frequency from
twice to once per day with a dose of 75 mg could determine a
significant reduction in the antiviral and antibacterial efficacy for
the ranges of ECS50 explored. In particular, from the best scenario
(ECS50 = 0.5 µM), the antiviral efficacy reduces from 47 to 43%
and the antibacterial efficacy from 9 to 4%. This reduction is
more pronounced in the worst case (ECS50 = 35 µM), where
both antiviral and antibacterial efficacy reduce approximately
to the half of those values presented for a dosage of twice per
day.
Against intuition, when the treatment duration is prolonged
to 10 days with dose of 75mg, this does not significantly
increase the antiviral and antibacterial efficacy for all the values
of ECS50. Concerning the antiviral efficacy, this result can be
mainly attributed to the positive feedback of the bacterial
secondary infection on IAV dynamics and in turn on the viral
area under the curve. On the other hand, the antibacterial
efficacy is also influenced, since the viral dynamics can modulate
the bacterial growth via macrophages deactivation and can
increase bacterial carrying capacity. The latter statement is also
one of the factors that could lead to the bimodal distribution
of the antibacterial efficacy histograms observed in all the
treatment strategies. Importantly, from our computational study,
the pharmacokinetic parameter ECS50 directly influences the
outcome of the Oseltamivir drug on IAV-Sp coinfection for all
the tested treatment regimens. On the contrary, it turns out
that the sensitivity of the antiviral and antibacterial efficacy to
the ECR50 parameter is low. This implies to presume that the
resistant mutant strain does not really affect the antiviral and
antibacterial efficacy. This is in agreement with in silico results
obtained in Canini et al. (2014) where the authors evaluated
the impact of Oseltamivir treatment strategies in the presence
of the emerging resistant strain. In fact, for the treatment
strategies considered in our work, the authors observed similar
values of the antiviral efficacy (Treanor et al., 2000) when
treatment is initiated at day 2 post infection. Therefore, our
results of antibacterial efficacy (9%) obtained with curative
regimen are lower than the experimental work of McCullers
(2004), reporting an antibacterial efficacy value of 25% formurine
data.
However, there are limitations in our simulation studies.
Concerning the applied model (1)–(12), we did not consider
the role of the immune response to clear the influenza virus. In
fact, our investigations cannot be applied with hosts shedding
preexisting immunity. Future studies should consider different
models for the viral infection including the dynamics of the
immune response such as CD8+T cells (Hancioglu et al.,
2007; Lee et al., 2009; Miao et al., 2010; Tridane and Kuang,
2010; Dobrovolny et al., 2013), Interferon type I (Canini and
Carrat, 2011; Pawelek et al., 2012; Hernandez-Vargas et al.,
2014) and Natural killer cells (Canini and Carrat, 2011). In
addition, the PK/PD dynamics have been estimated only for
adults (Wattanagoon et al., 2009). This implies that for other
groups such as children and seniors, our computational study
should be tested with appropriate PK/PD parameter estimates.
In fact for elderly, PK/PD parameters, e.g., apparent volume
of distribution (prolongation of elimination half-life) can have
important changes due to age modification in organ physiology
(Mangoni and Jackson, 2004).
In summary, we find that the actual recommended regimens
for Oseltamivir, i.e., curative and pandemic regimens may not
completely able to control the colonization of a secondary
bacterial coinfection. Higher doses, such as 150 and 300mg, are
recommended. Nevertheless, even this treatment regimen may
not control coinfection in case of low Oseltamivir effectiveness.
Moreover, our computational study suggests clear disadvantages
of reducing the intake frequency below twice per day for a
treatment duration of 5 and 10 days. Future clinical studies
are needed to verify our results towards improved therapeutic
treatments to fight coinfections (Dunning et al., 2014).
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